Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products.

Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metronidazole (500mg) and Nystatin (100,000 IU) in pessary dosage form. The product will be supplied in packs of 10 units (2 PVC/PE strips x 5 pessaries). The Company anticipates manufacturing and delivering 3 million pessaries per year.

MYCOFAGYL® is widely prescribed for the treatment of vaginal infections, including bacterial vaginosis and candidiasis (yeast infections). By combining the antibacterial and antiprotozoal action of Metronidazole with the antifungal action of Nystatin, MYCOFAGYL® provides a dual-action approach that helps restore balance and effectively treat common vaginal infections such as bacterial vaginosis and candidiasis.

This agreement highlights Cana's expertise in high-quality pharmaceutical manufacturing and expands its portfolio to include gynecology, adding to the wide range of therapeutic categories in which the company is active. By broadening its scope, Cana reinforces its position as a trusted partner to pharmaceutical companies across Europe and beyond.

Greg Siokas, CEO of Cosmos Health, stated: "We are excited to expand our order book with long-term, high-volume commitments, further reinforcing Cana's reputation as a reliable partner in the pharmaceutical industry. This agreement reflects our partner's confidence in Cana's quality, expertise, and state-of-the-art facilities, while MYCOFAGYL represents another step in our strategy to diversify our product offerings. Women's health remains a critical therapeutic area, and this agreement not only strengthens our manufacturing pipeline but also underscores the strong growth momentum of our contract manufacturing business and our ability to secure new high-margin contracts that strengthen our cash flow."

About Medical Pharmaquality S.A.

Medical Pharmaquality S.A., headquartered in Athens, Greece, is a diversified healthcare company engaged in the manufacture, distribution, and development of medicinal products for human use. Its portfolio spans a broad range of therapeutic areas, including infectious diseases, gastrointestinal health, metabolic disorders, cardiovascular disease, osteoporosis, neuropsychiatric conditions, respiratory health, joint health, and men's health, while also covering pharmacy-level wellness products and cosmetics through its affiliated brand M Cosmetics. With a focus on scientific rigor, quality, and regulatory compliance, Medical Pharmaquality S.A. provides partners with a robust platform for product development and distribution.

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company's expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company's plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that our facility with ATW Digital Asset Opportunities VII LLC will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company's planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications

[email protected]